Community Research Initiative of New England

Quick facts

Marketed products

• atazanavir/raltegravir · Infectious Disease
  This combination blocks HIV protease and integrase enzymes to prevent viral replication and reduce viral load in HIV-infected patients.
• atazanavir/tenofovir/emtricitabine · Infectious Disease / Virology
  This is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication through different mechanisms: atazanavir blocks protease, while tenofovir and emtricitabine inhibit reverse transcriptase.
• continue on current dual boosted PI · Infectious Disease / Virology
  Dual-boosted protease inhibitors block HIV protease to prevent viral replication and reduce viral load in HIV-infected patients.
• Darunavir (DRV/r) · Infectious Disease
  Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
• DRV/r · Infectious Disease
  DRV/r is a combination of darunavir (a protease inhibitor) boosted with ritonavir (a pharmacokinetic enhancer) that blocks HIV protease to prevent viral replication.
• Increased dose of Kaletra
• Intermitent Dosing
• Raltegravir plus Truvada

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Community Research Initiative of New England portfolio CI brief
• Community Research Initiative of New England pipeline updates RSS